强生达雷妥尤单抗进入“百亿美元俱乐部”几乎已无悬念之际，蓄势已久的CD38药物终于在2025年开年展现出了燎原态势。 2025年的第二周，CD38靶点 ...

1月24日，赛诺菲抗CD38单抗赛可益®（艾沙妥昔单抗注射液）获得国家药品监督管理局（NMPA）批准，用于与硼替佐米、来那度胺和地塞米松（VRd ...

CAR NK cells are following closely behind. Cytovia has designed CAR NK cells against three targets: EGFR, GPC3 and CD38. The EGFR candidate is a dual-targeted CAR designed to hit both wild-type ...

CARsgen Therapeutics Holdings Limited, a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumours, announces that KJ-C2320, an allogeneic CAR ...

ONK’s subsequent NK-cell therapy, ONKT102, has a CD38 CAR with optimised affinity and a DR5 TRAIL variant. ONKT102 is designed to treat relapsed or refractory multiple myeloma (MM), a highly ...

Natural killer (NK) cells are the human body’s first line of defense against cancer and infections but tend to get knocked down by treatment with anti-CD38 antibodies. This is because NK cells ...

The firm's products include CD38-GEAR-NK, CD38-Diagnostic and GEAR-NK Product. The company was founded in 2017 and is headquartered in Wexford, PA. Yesterday 8:39am ET COEPTIS Announces the Launch ...

an allogeneic CAR T-cell therapy targeting CD38, has administered the first dose to a patient in an investigator-initiated trial (IIT).

The firm's products include CD38-GEAR-NK, CD38-Diagnostic and GEAR-NK Product. The company was founded in 2017 and is headquartered in Wexford, PA.